Document Detail

Defibrillation threshold testing in patients with hypertrophic cardiomyopathy.
MedLine Citation:
PMID:  20663074     Owner:  NLM     Status:  In-Process    
INTRODUCTION: Implantable cardioverter-defibrillators (ICDs) decrease sudden cardiac death in patients with hypertrophic cardiomyopathy (HCM). One of the vital aspects of ICD implantation is the demonstration that the myocardium can be reliably defibrillated, which is defined by the defibrillation threshold (DFT). We hypothesized that patients with HCM have higher DFTs than patients implanted for other standard indications.
METHODS: We retrospectively reviewed the medical records of patients implanted with an ICD at the University of Maryland from 1996 to 2008. All patients with HCM who had DFTs determined were included. Data were compared to selected patients implanted for other standard indications over the same time period. All patients had a dual-coil lead with an active pectoral can system and had full DFT testing using either a step-down or binary search protocol.
RESULTS: The study group consisted of 23 HCM patients. The comparison group consisted of 294 patients. As expected, the HCM patients were younger (49 ± 18 years vs 63 ± 12 years; P < 0.00001) and had higher left ventricular ejection fractions (66% vs 32%; P < 0.000001). The average DFT in the HCM group was 13.9 ± 7.0 Joules (J) versus 9.8 ± 5.1 J in the comparison group (P = 0.0004). In the HCM group, five of the 23 patients (22%) had a DFT ≥ 20 J compared to 19 of 294 comparison patients (6%). There was a significant correlation between DFT and left ventricle wall thickness in the HCM group as measured by echocardiography (r = 0.44; P = 0.03); however, there was no correlation between DFT and QRS width in the HCM group (r = 0.1; P = NS).
CONCLUSIONS: Our results suggest that patients with HCM have higher DFTs than patients implanted with ICDs for other indications. More importantly, a higher percentage of HCM patients have DFTs ≥ 20 J and the DFT increases with increasing left ventricle wall thickness. These data suggest that DFT testing should always be considered after implanting ICDs in HCM patients.
Brett D Roberts; Robert E Hood; Magdi M Saba; Timm M Dickfeld; Anastasios P Saliaris; Stephen R Shorofsky
Related Documents :
18279244 - Potency of delta 9-thc and other cannabinoids in cannabis in england in 2005: implicati...
22507064 - Utilizing collagen membranes for guided tissue regeneration-based root coverage.
8462144 - Implantable transvenous cardioverter-defibrillators.
22134164 - Assessing the corrosion of biodegradable magnesium implants: a critical review of curre...
24683574 - Sensitivity of resonance frequency analysis for detecting early implant failure: a case...
10635184 - A technique for compensating for the loose ceraone screw.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pacing and clinical electrophysiology : PACE     Volume:  33     ISSN:  1540-8159     ISO Abbreviation:  Pacing Clin Electrophysiol     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7803944     Medline TA:  Pacing Clin Electrophysiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1342-6     Citation Subset:  IM    
Copyright Information:
©2010, The Authors. Journal compilation ©2010 Wiley Periodicals, Inc.
Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Proximity of right coronary artery to cavotricuspid isthmus as determined by computed tomography.
Next Document:  Differential entrainment distinguishes atrioventricular nodal reentry tachycardia from atrioventricu...